First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma. (2025). Journal of Kidney Cancer, 12(2), 27-36. https://doi.org/10.15586/jkcvhl.v12i2.387